TVRD
Tvardi Therapeutics, Inc.
$3.28
-0.52 (-13.68%)
At close · Jul 10
Market Cap
$30.77M
Shares
9,381,344
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.28
Open$3.84
Day$3.25–3.86
52W$1.50–43.65
Avg vol 30d4.2M
Short int507K · 5.4% float · 1.0d
Short vol45%
Last earningsMay 13, 2024
DataJan 2020–Jul 2026
Filing10-Q · May 8
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 8, 2026
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15 · calm
Equity put/call 0.55
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−48%
below
Price vs 50-day avg
+5%
above
RSI (14)
54
neutral
MACD trend
Positive
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+21%
trailing
6-month return
−27%
trailing
YTD return
−24%
this year
Relative strength
−36%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Distributing
1 of 66 funds reported for Jun 30 · net -49 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.41% of float · ▲ +27.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
66 holders — near 1-yr high, broad support
Squeeze score
75
high risk · 0–100
Fundamentals
Revenue growth
+959%
Y/Y
EPS growth
+71%
Y/Y
Free cash flow
$-24.5M
Balance sheet
$20.7M
net cash
Quant / Vol
risk profile
Volatility
147%
annualized · 1-yr
Max drawdown
−97%
past year
ATR
18.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−48%
Bearish
Price vs 50-day avg
+5%
Bullish
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross)
No cross
50d $3 › 200d $6 — 200d above 50d
Institutional flow
Distributing
1 of 66 funds reported for Jun 30 · net -49 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
5.41% of float · ▲ +27.5% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
66 holders — near 1-yr high, broad support
Price context
position in its 52-week range
52-wk low $2
Now $3 · 4%
52-wk high $44
vs 200-day avg -48%
vs 50-day avg +5%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
TVRD
this stock
Tvardi Therapeutics, Inc.
|
$30.77M | -23.7% | +959.3% | — | 5.4% |
|
ONC
BeOne Medicines Ltd.
|
$431.70B | -1.7% | +22179.2% | 878.5 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$123.19B | +7.1% | +46.2% | 28.8 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.63B | -13.8% | +20.8% | 16.2 | 3.3% |
|
ARGX
Argenx SE
|
$54.85B | +4.4% | — | — | 2.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| TVRD | +62.4% | +21.5% | -27.3% | +72.6% | -23.7% |
| SPY | +1.4% | +4.1% | +9.1% | +1.1% | +10.7% |
| vs SPY | +61.0% | +17.4% | -36.3% | +71.5% | -34.4% |